News and coverage
- May 2026Company newsRead article
Kariya and NeuraLight partner on digital eye-movement biomarkers
NeuraLight's oculometric platform will add an objective measure of brain function to the KP405 Phase II programme in Parkinson's.
- April 2026Company newsRead article
KP405 superior to tirzepatide in a Parkinson's model
A study in Frontiers in Endocrinology found KP405 protective in the 6-OHDA rat at a dose where tirzepatide showed no effect.
- March 2026Company news
KP405 brain biomarker results presented at AD/PD 2026
NeuroDex presented exploratory data from neuron-derived vesicles in healthy older adults and people with Parkinson's.
- November 2025CoverageRead article
Børsen: Danish biotech company presses on despite Novo failure
Børsen on Kariya after the results of Novo Nordisk's semaglutide trials in Alzheimer's disease.
- October 2025Company news
Kariya completes the Phase I trial of KP405
KP405 was safe and well tolerated in healthy volunteers, healthy older adults and people with Parkinson's.
- September 2025Company newsRead article
CNS Drugs publishes review by Christian Hölscher
The review covers GLP-1 and GIP receptor agonists as potential disease-modifying treatments for Alzheimer's and Parkinson's.
- July 2025CoverageRead article
PharmaBoardroom interviews Ian Laquian
Kariya's path from concept to clinical-stage company and the role of the Danish biotech ecosystem.
- June 2025CoverageRead article
National Geographic: the unexpected ways Ozempic-like drugs might fight dementia
The article mentions Kariya and quotes Christian Hölscher.
- May 2025Company news
First cohort completed in the KP405 multiple ascending dose study
Dosing began in the multiple ascending dose part of the Phase I trial at MAC Clinical Research, Manchester.
- March 2025Company news
MHRA approves amendments to the KP405 Phase I trial
The amendments added dose levels, healthy older adults, people with Parkinson's and a neuronal biomarker study.
- December 2024Company news
Single ascending dose study of KP405 completed
KP405 showed a favourable safety profile, consistent with other incretin analogues.
- September 2024CoverageRead article
Nature: why do obesity drugs seem to treat so many other ailments?
The editorial mentions Kariya and cites Christian Hölscher on brain penetrance.
- September 2024CoverageRead article
Nature: how rival weight-loss drugs fare at treating obesity, diabetes and more
Christian Hölscher on why brain penetrance matters for neurodegenerative disease.
- July 2024Company news
First participants dosed in the Phase I trial of KP405
The randomised, placebo-controlled first-in-human trial began at MAC Clinical Research in Manchester, UK.
- June 2024CoverageRead article
New Scientist: the surprising mental health and brain benefits of weight-loss drugs
The article includes Christian Hölscher.
- April 2024Company news
BNC Korea licenses KP405 and KP404 for five Asia-Pacific countries
An exclusive licence covering South Korea, Indonesia, Malaysia, Singapore and Thailand.
- April 2024Company news
BNC Korea makes a strategic investment in Kariya
BNC Korea (KOSDAQ: 256840) joined Kariya as a shareholder in a bridge financing round.
- November 2023Company news
UK MHRA authorises the Phase I trial of KP405
Clinical trial authorisation for the first-in-human study.
- June 2023Company news
Kariya submits its clinical trial application to the UK MHRA
The application covered a first-in-human study of safety, tolerability and pharmacokinetics.
- May 2023CoverageRead article
Reuters: after weight loss, Alzheimer's may be next frontier for drugs like Ozempic
Natalie Grover on the potential of GLP-1 drugs in Alzheimer's and Parkinson's disease.
- May 2023Company news
Kariya and MAC Clinical Research enter a financing and development partnership
MAC agreed to conduct the Phase I trial of KP405 and joined Kariya as a shareholder.
- April 2022Company news
Innovation Fund Denmark awards Kariya an InnoBooster grant
DKK 4.9 million towards the first-in-human studies of KP405.
- July 2021Company news
GLP toxicology studies of KP405 completed
The regulatory toxicology package needed to start human trials.
- December 2019Coverage
MedWatch: startup from Novo's incubator raises millions to find a cure for Parkinson's
MedWatch on Kariya's early funding at the BioInnovation Institute.